NCT07264959 2026-04-22
An Observational Study in Participants With Indolent Systemic Mastocytosis (ISM)
Blueprint Medicines Corporation
Recruiting
Clinical Trials
3 trialsNCT04910685 2026-04-20
(HARBOR) Study to Evaluate Efficacy and Safety of BLU-263 Versus Placebo in Patients With Indolent Systemic Mastocytosis
Blueprint Medicines Corporation
Phase 2/3 Recruiting
NCT07255638 2026-04-20
A Non-Interventional Study in Participants With Indolent Systemic Mastocytosis (ISM) in Germany
Blueprint Medicines Corporation
Recruiting